Journal of medical economicsHumansCarcinomaNon-Small-Cell LungCost-Benefit AnalysisLung Neoplasms
Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare payer perspective.
Nadia Karim, David Waterhouse, Simon Jones, Björn Stollenwerk
Published: 202510.1080/13696998.2025.2604968
Abstract
AIM: To evaluate the cost-effectiveness of sotorasib versus adagrasib in the second- and later lines of treatment for KRAS G12C non-small cell lung cancer (NSCLC) from a US private payer perspective. METHODS: A standard three-state partitioned surviv…
Preview only. Read the full abstract at the source